Global Information
회사소개 | 문의 | 비교리스트

세계의 혈장 시장 예측

Global Blood Plasma Market Forecast 2020-2028

리서치사 Inkwood Research
발행일 2020년 04월 상품 코드 640110
페이지 정보 영문 255 Pages
가격
US $ 2,500 ₩ 3,010,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,612,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,418,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 혈장 시장 예측 Global Blood Plasma Market Forecast 2020-2028
발행일 : 2020년 04월 페이지 정보 : 영문 255 Pages

세계 혈장 시장은 2020-2028년간 6.24%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다. 혈우병 환자 증가와 노인 인구 증가, 스포츠 부상 발생률 증가, 치료에서의 알부민 제제 사용 증가 등에 의해 시장 성장이 촉진될 전망입니다. 혈장은 백혈병이나 혈우병과 같은 일부 만성질환과의 싸움에서 필수적인 부분이 되고 있습니다. 면역 결핍은 심각한 감염의 주요 원인이 되고 있고, 세계 일부 지역에서 중요한 문제가 되고 있습니다. 신제품 출시 및 향상된 기능에 의해 시장에서의 혈장 제품 수요가 증가하고 있습니다. 한편, 이와 같은 치료법에 소용되는 비용과 혈액을 매개로 하는 질병의 감염 위험이 시장 성장을 저해하는 요인이 될 것으로 추정되고 있습니다.

세계의 혈장(Blood Plasma) 시장을 조사했으며, 시장 개요, 업계 구조, 투여경로·장애·혈장 유래 제품·적응증·최종사용자·지역별 시장 규모 추이 및 예측, 시장 성장 촉진요인 및 저해요인 분석, 과제, 시장 점유율, 경쟁 상황, 주요 기업 프로파일 등의 종합적인 정보를 제공합니다.

목차

제1장 조사 범위와 조사 방법

  • 조사 목적
  • 조사 범위
  • 조사 방법
  • 전제조건 및 제한

제2장 개요

  • 시장 규모와 예측
  • 시장 개요

제3장 시장 역학

  • 시장 정의
  • 주요 성장 촉진요인
    • 면역 글로불린을 기반으로 한 치료의 보급
    • 다른 치료 영역에서의 알부민 제제 사용 확대
    • 노인 인구 증가
    • 알파-1 항트립신 결핍증(AATD)의 유행
    • 혈우병 치료에서의 환자 풀 증가
    • 스포츠 부상 발생률 상승
  • 주요 성장 저해요인
    • 치료에서의 재조합 혈장 제품 사용 증가
    • 높은 혈장 치료 비용
    • 수혈후 부작용
    • 병원성 오염물질의 확산
    • 엄격한 규제

제4장 시장 분석

  • Porter's Five Forces 분석
    • 구매자의 교섭력
    • 공급 기업의 협상력
    • 신규 진출기업의 위협
    • 대체품의 위협
    • 경쟁기업간 경쟁도
  • 혈장 제제에 관한 규제
  • 임상 가이드라인
  • 기회 매트릭스
  • 벤더 상황
  • 주요 투자 인사이트

제5장 세계의 혈장 시장 : 투여 경로별

  • 수액
  • 스프레이
  • 바이오메디컬 실란트

제6장 세계의 혈장 시장 : 질환별

  • 면역결핍질환
  • 저감마글로불린 혈증
  • 혈우병
  • 폰 빌레브란트병(VWD)
  • 기타

제7장 세계의 혈장 시장 : 혈장 유래 제품별

  • 면역 글로불린 제제
    • 정맥 면역 글로불린 제제
    • 피하 면역 글로불린 제제
    • 기타
  • 알부민 제제
  • 고도면역
  • 혈액응고인자
  • 기타

제8장 세계의 혈장 시장 : 적응증별

  • 신경질환
  • 면역질환
  • 종양
  • 이식
  • 혈액질환
  • 류마티스
  • 호흡기질환
  • 기타

제9장 세계의 혈장 시장 : 최종사용자별

  • 병원/진료소
  • 연구실
  • 학술기관

제10장 세계의 혈장 시장 : 지역별

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 러시아
    • 벨기에
    • 폴란드
    • 기타
  • 아시아태평양
    • 일본
    • 중국
    • 호주 및 뉴질랜드
    • 인도
    • 한국
    • 태국
    • 인도네시아
    • 베트남
    • 기타
  • 기타 지역
    • 라틴아메리카
    • 중동 및 아프리카

제11장 기업 개요

  • ADMA BIOLOGICS
  • ARTHREX
  • BIO PRODUCTS LABORATORY
  • BAXTER INTERNATIONAL
  • BIOTEST AG
  • CERUS CORPORATION(CERUS)
  • CHINA BIOLOGIC PRODUCTS
  • CSL LIMITED
  • FUSION HEALTH CARE
  • GREEN CROSS HOLDINGS CORPORATION
  • GRIFOLS
  • LFB
  • OCTAPHARMA
  • TAKEDA PHARMACEUTICAL COMPANY
  • KEDRION BIOPHARMA INC
LSH 20.04.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - BLOOD PLASMA
  • TABLE 2: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL IMMUNODEFICIENCY DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL IMMUNODEFICIENCY DISEASES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL HYPOGAMMAGLOBULINEMIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL HYPOGAMMAGLOBULINEMIA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL HEMOPHILIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL HEMOPHILIA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL VON WILLEBRAND DISEASE (VWD) MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL VON WILLEBRAND DISEASE (VWD) MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL OTHER DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL OTHER DISORDERS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL OTHER IMMUNOGLOBULIN TYPE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL OTHER IMMUNOGLOBULIN TYPE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL ALBUMIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL ALBUMIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL HYPERIMMUNE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: GLOBAL HYPERIMMUNE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL OTHER PLASMA FRACTIONATION PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL OTHER PLASMA FRACTIONATION PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 34: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 36: GLOBAL NEUROLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: GLOBAL NEUROLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 38: GLOBAL IMMUNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 39: GLOBAL IMMUNOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 40: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 41: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 42: GLOBAL TRANSPLANTATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 43: GLOBAL TRANSPLANTATION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 44: GLOBAL HEMATOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 45: GLOBAL HEMATOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 46: GLOBAL RHEUMATOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 47: GLOBAL RHEUMATOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 48: GLOBAL PULMONOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 49: GLOBAL PULMONOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 50: GLOBAL OTHER THERAPEUTIC INDICATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 51: GLOBAL OTHER THERAPEUTIC INDICATION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 52: GLOBAL BLOOD PLASMA MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 53: GLOBAL BLOOD PLASMA MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 54: GLOBAL HOSPITALS AND CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 55: GLOBAL HOSPITALS AND CLINICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 56: GLOBAL RESEARCH LABORATORIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 57: GLOBAL RESEARCH LABORATORIES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 58: GLOBAL ACADEMIC INSTITUTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 59: GLOBAL ACADEMIC INSTITUTIONS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 60: GLOBAL BLOOD PLASMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 61: GLOBAL BLOOD PLASMA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 62: NORTH AMERICA BLOOD PLASMA MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 63: NORTH AMERICA BLOOD PLASMA MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 64: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, HISTORICAL YEARS 2016-2019 (IN $ MILLION)
  • TABLE 65: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 66: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 67: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 68: REST OF BLOOD PLASMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 69: REST OF BLOOD PLASMA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: IMMUNOGLOBULIN INFUSIONS SIDE EFFECTS
  • FIGURE 6: ROLE OF FIBRIN SEALANT IN COAGULATION CASCADE
  • FIGURE 7: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, IN 2019
  • FIGURE 8: GLOBAL BLOOD PLASMA MARKET, BY IMMUNODEFICIENCY DISEASE, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL BLOOD PLASMA MARKET, BY HYPOGAMMAGLOBULINEMIA, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL BLOOD PLASMA MARKET, BY HEMOPHILIA, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL BLOOD PLASMA MARKET, BY VON WILLEBRAND DISEASE (VWD), 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL BLOOD PLASMA MARKET, BY OTHER DISORDERS, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, IN 2019
  • FIGURE 14: GLOBAL BLOOD PLASMA MARKET, BY IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER IMMUNOGLOBULIN TYPES, 2020-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL BLOOD PLASMA MARKET, BY ALBUMIN, 2020-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL BLOOD PLASMA MARKET, BY HYPERIMMUNE, 2020-2028 (IN $ MILLION)
  • FIGURE 20: HYPERIMMUNES ISOLATION PROCESS
  • FIGURE 21: GLOBAL BLOOD PLASMA MARKET, BY COAGULATION FACTOR CONCENTRATES, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL BLOOD PLASMA MARKET, BY OTHER PLASMA FRACTIONATION PRODUCTS, 2020-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, IN 2019
  • FIGURE 24: GLOBAL BLOOD PLASMA MARKET, BY NEUROLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 25: GLOBAL BLOOD PLASMA MARKET, BY IMMUNOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL BLOOD PLASMA MARKET, BY ONCOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 27: GLOBAL BLOOD PLASMA MARKET, BY TRANSPLANTATION, 2020-2028 (IN $ MILLION)
  • FIGURE 28: GLOBAL BLOOD PLASMA MARKET, BY HEMATOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 29: GLOBAL BLOOD PLASMA MARKET, BY RHEUMATOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 30: LUPUS INFECTION SYMPTOMS
  • FIGURE 31: GLOBAL BLOOD PLASMA MARKET, BY PULMONOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 32: GLOBAL BLOOD PLASMA MARKET, BY OTHER THERAPEUTIC INDICATION, 2020-2028 (IN $ MILLION)
  • FIGURE 33: GLOBAL BLOOD PLASMA MARKET, BY END-USER, IN 2019
  • FIGURE 34: GLOBAL BLOOD PLASMA MARKET, BY HOSPITALS AND CLINICS, 2020-2028 (IN $ MILLION)
  • FIGURE 35: GLOBAL BLOOD PLASMA MARKET, BY RESEARCH LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 36: GLOBAL BLOOD PLASMA MARKET, BY ACADEMIC INSTITUTIONS, 2020-2028 (IN $ MILLION)
  • FIGURE 37: NORTH AMERICA BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 38: THE UNITED STATES BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 39: CANADA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: EUROPE BLOOD PLASMA MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 41: THE UNITED KINGDOM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 42: GERMANY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 43: FRANCE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 44: ITALY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: RUSSIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 46: BELGIUM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 47: POLAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 48: REST OF EUROPE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 49: ASIA PACIFIC BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 50: JAPAN BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 51: CHINA BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 52: AUSTRALIA & NEW ZEALAND BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 53: INDIA BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 54: SOUTH KOREA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 55: THAILAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 56: INDONESIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 57: VIETNAM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 58: REST OF ASIA PACIFIC BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 59: REST OF WORLD BLOOD PLASMA MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 60: LATIN AMERICA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 61: MIDDLE EAST & AFRICA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

KEY FINDINGS:

The global blood plasma market is projected to register a CAGR of 6.24% during the forecast period, 2020-2028. The eminent drivers of market growth are the increasing patient pool for hemophilia treatment, the rising geriatric population, the increasing occurrence of sports injuries, and the growing usage of albumin in therapeutic areas.

MARKET INSIGHTS:

Plasma is essential for the regulation of body functions. Blood Plasma comprises of several components that are useful, like coagulation factors, immunoglobulin, protease inhibitors, and albumin. It forms an essential part of therapeutic treatment for several therapies for its potential in combating several chronic diseases like leukemia and hemophilia. Immunodeficiency is a major factor responsible for severe infections, and has become a significant concern in several parts of the world. The new product launches and enhancements are augmenting the demand for blood plasma products in the market. At the same time, the expenses involved in such therapies, and the risk of blood-borne disease transmission, are the factors estimated to impede the growth of the market. The market faces challenges like a lack of a safe blood donor base, along with the shortage of plasma fractionation facilities. The competitive nature of the market is highly intense, and the market has the presence of a limited number of players.

MARKET INSIGHTS:

The global blood plasma market is segregated geographically into Europe, North America, Asia Pacific, and the rest of the world, for further analysis. The North American region held the largest market share in 2019. Inkwood Research estimates the region to continue the trend until the end of the forecast period. The region is considered to be the epicenter for blood plasma therapy research and development activities, which is incorporated into various treatment methods in the region.

COMPETITIVE INSIGHTS:

Some of the renowned companies registering their presence in the market include, Baxter International, Biotest AG, Takeda Pharmaceutical Company, Fusion Health Care, Arthrex, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
    • 3.2.2. GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
    • 3.2.3. GROWING GERIATRIC POPULATION
    • 3.2.4. RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
    • 3.2.5. INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
    • 3.2.6. RISE IN OCCURRENCE OF SPORTS INJURIES
  • 3.3. KEY RESTRAINTS
    • 3.3.1. INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
    • 3.3.2. HIGH COSTS OF BLOOD PLASMA TREATMENTS
    • 3.3.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
    • 3.3.4. SPREAD OF PATHOGENIC CONTAMINANTS
    • 3.3.5. HIGH REGULATIONS IN THE MARKET

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. PLASMA THERAPEUTICS REGULATION
  • 4.3. CLINICAL GUIDELINES
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY MODE OF DELIVERY

  • 5.1. INFUSION SOLUTIONS
  • 5.2. GELS
  • 5.3. SPRAYS
  • 5.4. BIOMEDICAL SEALANTS

6. MARKET BY DISORDER

  • 6.1. IMMUNODEFICIENCY DISEASE
  • 6.2. HYPOGAMMAGLOBULINEMIA
  • 6.3. HEMOPHILIA
  • 6.4. VON WILLEBRAND DISEASE (VWD)
  • 6.5. OTHER DISORDERS

7. MARKET BY BLOOD PLASMA DERIVATIVES

  • 7.1. IMMUNOGLOBULIN
    • 7.1.1. INTRAVENOUS IMMUNOGLOBULIN
    • 7.1.2. SUBCUTANEOUS IMMUNOGLOBULIN
    • 7.1.3. OTHER IMMUNOGLOBULIN TYPES
  • 7.2. ALBUMIN
  • 7.3. HYPERIMMUNE
  • 7.4. COAGULATION FACTOR CONCENTRATES
  • 7.5. OTHER PLASMA FRACTIONATION PRODUCTS

8. MARKET BY THERAPEUTIC INDICATION

  • 8.1. NEUROLOGY
  • 8.2. IMMUNOLOGY
  • 8.3. ONCOLOGY
  • 8.4. TRANSPLANTATION
  • 8.5. HEMATOLOGY
  • 8.6. RHEUMATOLOGY
  • 8.7. PULMONOLOGY
  • 8.8. OTHER THERAPEUTIC INDICATION

9. MARKET BY END-USER

  • 9.1. HOSPITALS AND CLINICS
  • 9.2. RESEARCH LABORATORIES
  • 9.3. ACADEMIC INSTITUTIONS

10. GEOGRAPHICAL ANALYSIS

  • 10.1. NORTH AMERICA
    • 10.1.1. THE UNITED STATES
    • 10.1.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. THE UNITED KINGDOM
    • 10.2.2. GERMANY
    • 10.2.3. FRANCE
    • 10.2.4. ITALY
    • 10.2.5. RUSSIA
    • 10.2.6. BELGIUM
    • 10.2.7. POLAND
    • 10.2.8. REST OF EUROPE
  • 10.3. ASIA PACIFIC
    • 10.3.1. JAPAN
    • 10.3.2. CHINA
    • 10.3.3. AUSTRALIA & NEW ZEALAND
    • 10.3.4. INDIA
    • 10.3.5. SOUTH KOREA
    • 10.3.6. THAILAND
    • 10.3.7. INDONESIA
    • 10.3.8. VIETNAM
    • 10.3.9. REST OF ASIA PACIFIC
  • 10.4. REST OF WORLD
    • 10.4.1. LATIN AMERICA
    • 10.4.2. MIDDLE EAST & AFRICA

11. COMPANY PROFILES

  • 11.1. ADMA BIOLOGICS
  • 11.2. ARTHREX
  • 11.3. BIO PRODUCTS LABORATORY
  • 11.4. BAXTER INTERNATIONAL
  • 11.5. BIOTEST AG
  • 11.6. CERUS CORPORATION (CERUS)
  • 11.7. CHINA BIOLOGIC PRODUCTS
  • 11.8. CSL LIMITED
  • 11.9. FUSION HEALTH CARE
  • 11.10. GREEN CROSS HOLDINGS CORPORATION
  • 11.11. GRIFOLS
  • 11.12. LFB
  • 11.13. OCTAPHARMA
  • 11.14. TAKEDA PHARMACEUTICAL COMPANY
  • 11.15. KEDRION BIOPHARMA INC
Back to Top
전화 문의
F A Q